Focus Biomolecules is delighted to announce our 2026 AACR Travel Grant awardees, Shujah Rehman (grad student at The University of Kansas) and Nabamita Boruah (postdoc at
FOCUS on New Cancer Therapeutic Targets. Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality and is largely driven by metabolic disorders such as obesity
FOCUS on New Drug Approvals. On April 13th the FDA approved Travere Therapeutics’ Sparsentan (Filspari) as the first approved treatment for reduction of proteinuria in adult
FOCUS on Mitochondrial Disease. Leigh syndrome (LS) is a mitochondrial disease characterized by neurodevelopmental regression and muscle weakness with early death following metabolic crises. In a
Focus Biomolecules will be exhibiting at the annual meeting of American Association for Cancer Research in San Diego, April 19 – 22. Stop by our booth
FOCUS on a New Pharma Success Story. Day One Biopharmaceuticals is only 8 years old, yet in that short period of time it bought the rights
BOGO
